Patents by Inventor William T. McMillen

William T. McMillen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminopyridyloxypyrazole compounds
    Patent number: 9617243
    Abstract: The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF?R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 11, 2017
    Assignee: Eli Lilly and Company
    Inventors: William T. McMillen, Sajan Joseph, Huaxing Pei, Jason Scott Sawyer, Gaiying Zhao, David A. Coates, Craig D. Wolfangel
  • ERK inhibitors
    Patent number: 9469652
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 18, 2016
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
  • ERK INHIBITORS
    Publication number: 20160176896
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
  • AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS
    Publication number: 20160096823
    Abstract: The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF?R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.
    Type: Application
    Filed: September 30, 2015
    Publication date: April 7, 2016
    Inventors: William T. MCMILLEN, Sajan JOSEPH, Saravanan PARTHASARATHY, Huaxing PEI, Jason Scott SAWYER, Douglas W. BEIGHT, Gaiying ZHAO, David A. COATES, Craig D. WOLFANGEL
  • Ketolide antibiotics
    Patent number: 6833444
    Abstract: This invention relates to compounds of the formula 1: and to pharmaceutically acceptable salts and solvates thereof wherein X1, X2, R2, R8, R9, R10 and R11 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: December 21, 2004
    Assignee: Pfizer, Inc.
    Inventors: William T. McMillen, Takushi Kaneko
  • Ketolide antibiotics
    Publication number: 20020156027
    Abstract: This invention relates to compounds of the formula 1 1
    Type: Application
    Filed: April 5, 2002
    Publication date: October 24, 2002
    Inventors: William T. McMillen, Takushi Kaneko
  • Synthesis of carbamate ketolide antibiotics
    Patent number: 6403776
    Abstract: The invention relates to a method of preparing a macrolide antibiotic of the formula wherein R1, R2, R3, R4, R5 are defined above. These antibiotics are useful as antibacterial and antiprotozoal agents in mammals, including man, as well as in fish and birds. The invention also includes novel compounds made by the preparation of the macrolide antibiotic.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc.
    Inventors: David H. B. Ripin, Brian C. Vanderplas, Takushi Kaneko, William T. McMillen, Robert W. McLaughlin
  • ERK inhibitors
    Patent number: RE48635
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: July 13, 2021
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao